Evolution of secondary hematologic disorders: preMDS-->MDS-->sAML.
Preisler
H D
HD
Rush Cancer Institute, Rush-Presbyterian-St. Luke's Medical Center, Rush University, Chicago, IL, USA.
D000208:Acute Disease; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology; D001854:Bone Marrow Cells / Q000187:drug effects / Q000473:pathology; D002455:Cell Division; D002478:Cells, Cultured / Q000473:pathology; D002869:Chromosome Aberrations; D002877:Chromosomes, Human / Q000235:genetics / Q000648:ultrastructure; D002999:Clone Cells / Q000473:pathology; D016207:Cytokines / Q000502:physiology; D004195:Disease Models, Animal; D018450:Disease Progression; D015973:Gene Expression Regulation, Leukemic; D016147:Genes, Tumor Suppressor; D020022:Genetic Predisposition to Disease; D006410:Hematopoiesis; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000473:pathology; D006801:Humans; D007951:Leukemia, Myeloid / Q000209:etiology / Q000235:genetics / Q000473:pathology*; D008223:Lymphoma / Q000473:pathology / Q000628:therapy; D051379:Mice; D008822:Mice, Transgenic; D009190:Myelodysplastic Syndromes / Q000235:genetics / Q000473:pathology*; D009196:Myeloproliferative Disorders / Q000473:pathology; D016609:Neoplasms, Second Primary / Q000209:etiology / Q000473:pathology; D009857:Oncogenes; D011289:Preleukemia / Q000235:genetics / Q000473:pathology*
D000970:Antineoplastic Agents; D016207:Cytokines